IL161665A0 - Method of administering a thymosin alpha 1 peptide - Google Patents

Method of administering a thymosin alpha 1 peptide

Info

Publication number
IL161665A0
IL161665A0 IL16166502A IL16166502A IL161665A0 IL 161665 A0 IL161665 A0 IL 161665A0 IL 16166502 A IL16166502 A IL 16166502A IL 16166502 A IL16166502 A IL 16166502A IL 161665 A0 IL161665 A0 IL 161665A0
Authority
IL
Israel
Prior art keywords
peptide
thymosin alpha
administering
patient
immune
Prior art date
Application number
IL16166502A
Other languages
English (en)
Original Assignee
Sciclone Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sciclone Pharmaceuticals Inc filed Critical Sciclone Pharmaceuticals Inc
Publication of IL161665A0 publication Critical patent/IL161665A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2292—Thymosin; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Biotechnology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
IL16166502A 2001-11-01 2002-11-01 Method of administering a thymosin alpha 1 peptide IL161665A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33087401P 2001-11-01 2001-11-01
PCT/US2002/035093 WO2003037366A1 (en) 2001-11-01 2002-11-01 Method of administering a thymosin alpha 1 peptide

Publications (1)

Publication Number Publication Date
IL161665A0 true IL161665A0 (en) 2004-09-27

Family

ID=23291672

Family Applications (2)

Application Number Title Priority Date Filing Date
IL16166502A IL161665A0 (en) 2001-11-01 2002-11-01 Method of administering a thymosin alpha 1 peptide
IL161665A IL161665A (en) 2001-11-01 2004-04-29 Use of thymosin alpha 1 peptide in the manufacture of a pharmaceutical composition

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL161665A IL161665A (en) 2001-11-01 2004-04-29 Use of thymosin alpha 1 peptide in the manufacture of a pharmaceutical composition

Country Status (19)

Country Link
US (2) US20050049191A1 (ja)
EP (1) EP1450850B1 (ja)
JP (1) JP2005511563A (ja)
KR (1) KR20050042229A (ja)
CN (1) CN1582163A (ja)
AT (1) ATE481980T1 (ja)
AU (1) AU2002363248B2 (ja)
BR (1) BR0213823A (ja)
CA (1) CA2464307A1 (ja)
DE (1) DE60237784D1 (ja)
EA (1) EA008536B1 (ja)
ES (1) ES2353379T3 (ja)
IL (2) IL161665A0 (ja)
MX (1) MXPA04004187A (ja)
NO (1) NO327101B1 (ja)
NZ (1) NZ532763A (ja)
PL (1) PL208388B1 (ja)
UA (1) UA80957C2 (ja)
WO (1) WO2003037366A1 (ja)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20050086819A (ko) * 2002-11-25 2005-08-30 시클론 파마수티컬 인코포레이티드 알파 티모신을 사용한 방사능 손상에 대한 보호방법
BRPI0408892A (pt) * 2003-03-28 2006-04-11 Sciclone Pharmaceuticals Inc uso de timosina alfa 1 para tratar as infecções por arpergillus
US8017129B2 (en) 2006-06-15 2011-09-13 SciClone Pharmaceuticals International Ltd Use of thymosin alpha 1 for preparing a medicament for the treatment of stage IV malignant melanoma
US20080300166A1 (en) * 2007-06-01 2008-12-04 Sciclone Pharmaceuticals, Inc. Treatment of Melanoma with Alpha Thymosin Peptides
AU2008338594A1 (en) * 2007-12-14 2009-06-25 Sciclone Pharmaceuticals, Inc. Treatment of melanoma with alpha thymosin peptides in combination with an antineoplastic heat shock apoptosis activator (HSAA)
CN102458470B (zh) 2009-05-08 2016-01-20 赛生制药有限公司 作为疫苗增强剂的α胸腺素肽
WO2013134666A1 (en) * 2012-03-08 2013-09-12 Sciclone Pharmaceuticals, Inc. Use of thymosin alpha for treatment of purulent rhinosinusitis
US20130296223A1 (en) 2012-03-30 2013-11-07 Sciclone Pharmaceuticals, Inc. Use of thymosin alpha for the treatment of sepsis
ES2882080T3 (es) * 2014-10-21 2021-12-01 Sciclone Pharmaceuticals Int Ltd Tratamiento del cáncer con estimuladores inmunitarios
EP3256150B1 (en) * 2015-02-09 2020-12-09 SciClone Pharmaceuticals International Ltd. Thymosin alpha 1 for use in treatment of cystic fibrosis

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4447233A (en) * 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4444757A (en) * 1981-11-16 1984-04-24 Research Corporation Use of thymosin as an anti-diabetes and anti-hypertensive disease agent
TW224053B (ja) * 1991-09-13 1994-05-21 Paul B Chretien
US5468729A (en) * 1993-10-26 1995-11-21 Alpha 1 Biomedicals Method for treatment of autoimmune hepatitis
US5760000A (en) * 1994-05-13 1998-06-02 University Technologies International,Inc. Inhibition of liver cancer by the use of GnRH and GnRH analogs
US5888980A (en) * 1994-06-30 1999-03-30 Bio-Logic Research And Development Corporation Compositions for enhancing immune function
US5632983A (en) * 1994-11-17 1997-05-27 University Of South Florida Method for treating secondary immunodeficiency
US5849596A (en) * 1996-07-08 1998-12-15 Food Industry Research And Development Institute Process for determining the smoke content of edible oil
ATE342959T1 (de) * 2000-07-14 2006-11-15 Transform Pharmaceuticals Inc System und verfahren zum optimieren des gewebebarrieretransfers von verbindungen
AU2002241596A1 (en) * 2000-11-02 2002-06-18 Research Foundation Of City University Of New York Methods for stimulating nervous system regeneration and repair by inhibition phosphodiesterase type 4

Also Published As

Publication number Publication date
ATE481980T1 (de) 2010-10-15
NO20042100L (no) 2004-05-21
MXPA04004187A (es) 2004-07-08
ES2353379T3 (es) 2011-03-01
EA008536B1 (ru) 2007-06-29
EA200400591A1 (ru) 2004-10-28
US20100221274A1 (en) 2010-09-02
BR0213823A (pt) 2004-08-31
PL370430A1 (en) 2005-05-30
EP1450850B1 (en) 2010-09-22
AU2002363248B2 (en) 2007-11-22
NO20042100D0 (no) 2004-05-21
EP1450850A4 (en) 2005-11-30
US20050049191A1 (en) 2005-03-03
JP2005511563A (ja) 2005-04-28
WO2003037366A1 (en) 2003-05-08
PL208388B1 (pl) 2011-04-29
CA2464307A1 (en) 2003-05-08
DE60237784D1 (de) 2010-11-04
UA80957C2 (en) 2007-11-26
EP1450850A1 (en) 2004-09-01
CN1582163A (zh) 2005-02-16
NZ532763A (en) 2008-01-31
NO327101B1 (no) 2009-04-20
IL161665A (en) 2011-03-31
KR20050042229A (ko) 2005-05-06

Similar Documents

Publication Publication Date Title
EP0637239A4 (en) METHOD FOR PROMOTING NITROGEN RETENTION IN PEOPLE.
WO2001060381B1 (en) Nucleoside analogs with carboxamidine-modified bicyclic base
DK0490991T3 (da) Doseringsform til oral administration af hypoglykæmisk glipizid
MXPA05006572A (es) Composiciones y metodos para la administracion mejorada por via mucosa de peptidos fijadores al receptor de y2 y metodos para tratar y prevenir la obesidad.
IL208184A0 (en) Glp-1, and methods for treating diabetes
WO1987004076A1 (en) Low dosage of interferon to enhance vaccine efficiency
DE60327843D1 (de) Arzneimittelformulierungen mit verzögerter freisetzung mit einem trägerpeptid
BG106171A (en) Compositions and uses of et743 for treating cancer
IL161665A0 (en) Method of administering a thymosin alpha 1 peptide
MY103746A (en) Improvements in or relating to somatostatins
EA200400548A1 (ru) Лечение тяжёлой пневмонии путём введения ингибитора пути тканевого фактора (tfpi)
IL161670A0 (en) Thymosin alpha 1 peptide/polymer conjugates
DK1173476T3 (da) Funktionelle sojabönneproteiner
AR023185A1 (es) Tratamiento de cancer mejorado con temozolomida
MY106603A (en) Treatment of genital warts with a combination of liquid nitrogen and recombinant dna human alpha interferon
TW200517119A (en) Method of treatment using interferon-tau
WO2003072019A3 (en) Sequential therapy comprising a 20(s)-camptothecin compound and a pyrimidine base analog
FR2693907B1 (fr) Procédé d'administration de solutions de facteur de stimulation des colonies granulocytaires.
JPS6447715A (en) Improver for ovulation inductive pregnant genital physiological dysfunction
MD197G2 (ro) Preparat şi procedeu de tratare a hipogalactiei
MD1780F1 (en) Method of treatment of patients with hepatic cirrhosis
AU4918900A (en) Interferon-beta use in the treatment of ewing's family of tumors
MD1469G2 (ro) Metodă de tratament al şocului combustional
UA11276C2 (uk) Спосіб реабілітації хворих, які переhесли вірусhий гепатит
AU8716001A (en) Treatment of hepatitis c with thymosin and pegylated interferon

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed